
    
      We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD
      regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment.
      After achievement of response, patients either underwent hematopoietic stem cell
      transplantation (HSCT) or consolidation with hyper-CVAD.
    
  